This Foley Executive Briefing Series program examined the common sources of litigation for life sciences companies as well as methods for mitigating exposure when these issues arise.
The program explored the potential litigation challenges that arise in light of intellectual property (IP) issues, IP ownership challenges arising out of collaborations or movements of personnel, and conflicts of interest in research, and addressed their implications for life sciences companies.
Questions that were discussed include:
- What are the key exposure areas for life sciences companies?
- What is involved in litigating these issues?
- What types of relief may be sought?
- What does litigation cost?
- Are there alternatives to litigation?
This interactive program was moderated by Foley Partners J. Mark Waxman and Thomas I. Elkind.
People
Related Insights
May 29, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
May 29, 2025
Foley Viewpoints
Supreme Court Clarifies Scope of Federal Fraud Statutes in Connection with False DBE Reporting on Federally Funded Projects
On May 22, 2025, the U.S. Supreme Court issued a significant decision in Kousisis v. United States, affirming a six-year prison sentence for a contractor convicted of federal wire fraud for misrepresenting use of a disadvantaged business enterprise supplier on a project.
May 29, 2025
Foley Viewpoints
Keep Wining: Franchise Statute Opens Door to Protections for Missouri Wine Distributor
The Eighth Circuit recently applied a novel, broad reading of the Missouri Franchise Act granting franchise protection to distributors…